News

Xywav is an oxybate product with a unique composition of cations resulting in 92 percent less sodium – or approximately 1,000 to 1,500 mg/night – than sodium oxybate

BNT162, which is being developed for giving protection against SARS-CoV-2, the virus that causes Covid-19, was recently given the fast track designation by the US Food and Drug

The trial will enroll patients who are not responding to medication and are unsuitable for coronary artery bypass graft or percutaneous coronary intervention. XC001 is an investigational novel

According to Jnana Therapeutics, the small molecule drugs will be developed for targeting the solute carrier (SLC) family of metabolite transporters for regulating cellular metabolism. The Massachusetts-based biotech

The FDA has granted Priority Review for the NDA, which provides an expedited six month review, and has assigned a Prescription Drug User Fee Act (PDUFA) target action

Gilead is also provided with an exclusive option to purchase the remaining stake in Tizona for up to an additional $1.2bn. The deal is also comprised of an

Financial details of the agreement were not disclosed, but the terms were based on the timing of delivery and the volume of doses. “In the face of this

Terms of the transaction were not disclosed. Dr. Cheng Liu, Founder and President of Eureka Therapeutics, will join the Board of Directors of JW Therapeutics, and Victor Shum,

The companies have signed a collaboration agreement for the research, development, manufacturing and commercialisation of up to five messenger RNA (mRNA)-based vaccines and monoclonal antibodies (mAbs) to eliminate